Important note: Information in this article was accurate in October 2007. The state of the art may have changed since the publication date.
Risk factors for early mortality for children receiving divided adult fixed dose combination tablets in Malawi
HIV Treatment Bulletin - Vol. 8, No. 10, October 2007
National treatment scale up in Malawi initially did not serve children well due to concerns about using divided adult fixed dose combination (FDC) tablets and a shortage of healthcare workers trained in paediatric HIV.
Since 2006, national guidelines include more information about the management of children on ART, health workers have been trained and regional pharmacokinetic and clinical studies have provided reassuring data for divided FDCs. By September 2006, 4612 children aged 14 years or younger had started ART in the Malawi state programme.
A paper published in the August 20, 2007 edition of AIDS, authored by Bong and coworkers from Malawi and the Taiwan Medical Mission reported findings from a study that looked at risk factors for early death in children initiating ART.
In Malawi treatment outcomes for patients on ART are monitored monthly using ART patient “master cards”. As of September 2006, according to the Ministry of Health figures, 7983/69547 patients (11%) started on ART had died. In adults, 70% of these deaths occurred in the first three months of treatment.
The study was conducted at the Mzuzu Central Hospital, which is the main referral hospital in the northern region of Malawi. HIV-positive children eligible for ART by WHO criteria receive a thorough clinical assessment before starting treatment. Their guardians receive counseling and education about how to give children divided tablets.
For the first two weeks children receive a single daily divided tablet, FDC, of d4T 30 mg (T30) or 40 mg (T40)/ 3TC 150 mg/ nevirapine 200 mg in the morning followed by a single daily divided tablet of d4T 30 mg or 40 mg/3TC 150 mg in the evening. If there are no nevirapine side effects, the children will then receive divided tablets, FDC, T30 or T40 twice a day.
Doses are based on body weight in accordance with national guidelines. Since December 2005, all children have been treated with the d4T 30 mg formulation only, as these provide a higher dose of nevirapine compared with d4T for all weight bands: pharmacokinetic studies in Malawi showed that children were underdosed with nevirapine when half to quarter tablets of T40 were used. Children also receive cotrimoxazole preventive therapy.
Of 439 children enrolled in the study, 220 (50%) were boys. The median age was 6 years (IQR 2.9–9.7 years). 37 children (8%) were aged less than 18 months (range 3.6–16.9 months; IQR 12–15.6 months), 172 (39%) were aged 18 months to 5 years (range 1.5–5.9 years; IQR 2.2–4.5 years) and 230 (52%) were aged 6–14 years (range 6–14 years; IQR 7.5–11.5).
The very young children, aged less than 18 months, were significantly more likely to have an advanced WHO clinical stage and severe wasting compared with the other children.
By September 2006, the outcomes of the 439 children were: 306 (69%) alive and on ART; 38 (8.6%) lost to follow; and 46 (10.4%) transferred to another ART clinic.
The investigators reported, of the live children, the percentage with a CD4 cell count indicating that they were not severely immunodeficient increased from 54% at baseline (n=408) to 75% at 3 months (n=209) to 85% at 6 months (n=138). 49 children (11%) died; 35 (71%) died in the first 3 months and 44 (89%) in the first 6 months of treatment. The cumulative incidence of death at 3, 6, 12 and 24 months after ART was 8, 12, 13 and 15%, respectively.
By multivariate analysis, children in WHO clinical stage 4, with severe wasting and with a CD4 cell count below the threshold for severe immunodeficiency had a significant risk of early death at 3 or 6 months.
In the discussion, the investigators note the limitations of this operational research study:
They identified reasons for early mortality as: late diagnosis - particularly in the youngest children; late presentation at health facilities; and life-threatening complications such as bacteraemia.
In order to prevent these early deaths they recommend that:
In conclusion they wrote: “The final challenge is to scale up PMTCT to prevent children becoming HIV infected in the first place.”
2007-10-10
IB070810-17
©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.